# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re F	Patent A	pplication of	)		
Christer NORDSTEDT et al.			) Group Art Unit: Unassigned		
Application No.: Unassigned			) Examiner: Unassigned	Inf.1	
Filed:	May 8,	, 2001	) Examiner: Unassigned )  )  >	186	
For:		IDE BINDING KLVFF- ENCE OF AMYLOID BETA	) ) ) 1010		
			SCLOSURE STATEMENT		
		missioner for Patents O.C. 20231			
Sir:					
above-		sed is an Information Disclosure ed patent application.	Statement and accompanying form PTO-1449 for the	he	
	[X]	No additional fee for submissi	on of an IDS is required.		
	[ ] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.				
	[ ] A certification under 37 C.F.R. § 1.97(e) is also enclosed.				
	[ ] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.				
	[]	Charge \$to Dep	posit Account No. 02-4800 for the fee due.		
	[]	A check in the amount of \$	is enclosed for the fee due.		
	6, 1.17		ed to charge any appropriate fees under 37 C.F.R. by this paper, and to credit any overpayment, to submitted in duplicate.		
			Respectfully submitted,		
Alexar	Box 1404 ndria, V 836-662	irginia 22313-1404	BURNS, DOANE, SWECKER & MATHIS, L.L.P.  By: Mercedes K Meyer  Registration No. 44/939		

Date: May 8, 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	T T
Christer NORDSTEDT et al.	) Oroup Art Unit: Unassigned )	85006 85006
Application No.: Unassigned	) Examiner: Unassigned	3.1046 09/
Filed: May 8, 2001	)	, <u>==</u>
For: PEPTIDE BINDING KLVFF- SEQUENCE OF AMYLOID BETA	) ) )	

#### INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98. Copies of each of the documents cited below were submitted in U.S. Serial No. 09/095/106, of which this is a divisional application. Applicants are not required to provide copies of the documents in view of MPEP § 609. Thus, Applicants are not providing copies of the documents.

### **U.S. Patent Documents**

- U.S. Patent No. 5,578,451 to Ikuo Nishimoto, issued November 26, 1996;
- U.S. Patent No. 5,470,951 to Eugene Roberts, issued November 28, 1995; and
- U.S. Patent No. 5,854,204 to Mark A. Findeis et al., issued December 29, 1998.

## **Foreign Patent Documents**

PCT Publication No. WO 95/08999, published April 6, 1995;

European Patent Publication No. 0 584 452 A1, published March 2, 1994;

PCT Publication No. WO 94/19692, published September 1, 1994;

PCT Publication No. WO 96/34887, published November 7, 1996; and

PCT Publication No. WO 94/14836, published July 7, 1994.

#### **Other Documents**

Lars O. Tjernberg et al., "Arrest of β-Amyloid Fibril Formation by a Pentapeptide Ligand", J. Biol. Chem., Vol. 271, No. 15, pp. 8545-8548, April 12, 1996, The American Society for Biochemistry and Molecular Biology, Inc., USA.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

(703) 836-6620

P.O. Box 1404

Date: May 8, 2001

Alexandria, Virginia 22313-1404



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.